Anti-β-Gal-IgA2 isotype control

Recombinant monoclonal human IgA2 antibody against E. coli β-galactosidase

InvivoGen offers an isotype control for InvivoGen’s IgA2 monoclonal antibody (mAb) collection. Anti-β-Gal-IgA2 is a human IgA2 mAb targeting E. coli β-galactosidase (β-Gal).

It features the constant region of the human IgA2 isotype and the variable region of Mouse IgG2a Control (clone: T9C6) targeting E. coli β-Gal. Therefore, it cannot react with human targets.

It was generated by recombinant technology, produced in Chinese hamster ovary (CHO) cells, and purified by affinity chromatography.

Specifications

Specificity: E. coli β-galactosidase

Clonality: Monoclonal

Clone: T9C6

Isotype: Human IgA2, kappa

Source: CHO cells

Formulation: 0.2 μm filtered solution in Tris/glycine with 5% saccharose

Purity: Affinity chromatography purified

Application: Negative control for the following human IgA2 antibodies (see below)

Quality control:

• The absence of binding of Anti-β-Gal-hIgA2 to human cell lines has been controlled using flow cytometry.
• The absence of endotoxins and other bacterial contaminants has been confirmed using HEK-Blue™ TLR4 and HEK-Blue™ TLR2 cells.

Please use Anti-β-Gal-hIgA2 for the following antibodies:

• Anti-hCD20-hIgA2
• Anti-hTNF-α-hIgA2
• HER2-Tra-hIgA2
• Anti-hRANKL-hIgA2
• Anti-hCTLA4-hIgA2
• Anti-hPD1-Ni-hIgA2
• Anti-hPD1-Pem-hIgA2
• Anti-hCD20-Ga-hIgA2
• Anti-hCD20-Of-hIgA2
• Anti-hEGFR-hIgA2
• Anti-hVEGF-hIgA2
• Anti-hIFNγ-hIgA2
• Anti-hTLR2-IgA2
• Anti-hTLR5-IgA2

Contents

• bgal-mab7: 200 µg purified Anti-β-Gal-IgA2 antibody, provided azide-free and lyophilized
• bgal-mab7-1: 1 mg purified Anti-β-Gal-IgA2 antibody, provided azide-free and lyophilized

The product is shipped at room temperature.

 Upon receipt, store lyophilized antibody at -20°C.

Details

The human IgA2 is found predominantly in secretory lymphoid tissues, where it plays a critical role in mucosal immunity. It is highly resistant to enzymatic degradation by bacterial proteases, due to a short hinge region. IgA2 displays no complement-dependent cytotoxicity (CDC) and low antibody-dependent cell-mediated cytotoxicity (ADCC).